We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
Read MoreHide Full Article
SpringWorks Therapeutics (SWTX - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending conditional marketing authorization for its MEK inhibitor, mirdametinib, for a rare genetic disorder.
The CHMP has recommended granting a conditional marketing authorization to mirdametinib for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients with neurofibromatosis type 1 (NF1) aged two years and above.
The European Commission will now review the CHMP’s opinion and a decision from the regulatory body is expected in the third quarter of 2025. The EMA validated the marketing authorization application (MAA) for mirdametinib last August.
If approved, mirdametinib would become the first and only therapy to receive marketing authorization for treating adults and children with NF1-PN in the European Union.
The FDA approved mirdametinib under the brand name Gomekli for treating adult and pediatric patients aged two years and older with NF1-PN in February 2025. Gomekli generated sales worth $4.9 million in the United States during the first quarter of 2025.
Year to date, shares of SpringWorks have risen 28.6% against the industry’s decline of 5.5%.
Image Source: Zacks Investment Research
SWTX Set to be Acquired by Merck KGaA
In April 2025, Merck KGaA, Darmstadt, Germany, announced that it had agreed to acquire SpringWorks for $47 per share in cash, representing a total equity value of approximately $3.9 billion.
The transaction is expected to be closed in the second half of 2025, subject to customary closing conditions.
The acquisition of SpringWorks will add its oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), to Merck KGaA’s portfolio.
Ogsiveo was approved in the United States for treating adult patients with desmoid tumors in November 2023. Ogsiveo is the first and only FDA-approved treatment indicated specifically for desmoid tumors.
Ogsiveo generated sales worth $172 million in 2024. In the first quarter of 2025, the drug recorded sales of $44.1 million in the United States.
Several label expansion studies on Ogsiveo, targeting different cancer indications, are currently ongoing.
Notably, the EMA validated the MAA for Ogsiveo for the treatment of adult patients with desmoid tumors in February 2024. The CHMP’s opinion related to the MAA for Ogsiveo is expected later in the second quarter of 2025.
The impending acquisition by Merck KGaA will help SpringWorks to reach global markets and build on the resources, helping more patients with such rare tumors.
SWTX's Zacks Rank & Stocks to Consider
SpringWorks currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for Halozyme’s earnings per share have increased from $5.02 to $5.23 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.56 to $6.77. Year to date, shares of HALO have risen 14.1%.
HALO’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.60%.
In the past 60 days, estimates for Lexicon’s loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 10.7%.
LXRX’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%.
In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 14.5%.
AMRN’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
SpringWorks Therapeutics (SWTX - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending conditional marketing authorization for its MEK inhibitor, mirdametinib, for a rare genetic disorder.
The CHMP has recommended granting a conditional marketing authorization to mirdametinib for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients with neurofibromatosis type 1 (NF1) aged two years and above.
The European Commission will now review the CHMP’s opinion and a decision from the regulatory body is expected in the third quarter of 2025. The EMA validated the marketing authorization application (MAA) for mirdametinib last August.
If approved, mirdametinib would become the first and only therapy to receive marketing authorization for treating adults and children with NF1-PN in the European Union.
The FDA approved mirdametinib under the brand name Gomekli for treating adult and pediatric patients aged two years and older with NF1-PN in February 2025. Gomekli generated sales worth $4.9 million in the United States during the first quarter of 2025.
Year to date, shares of SpringWorks have risen 28.6% against the industry’s decline of 5.5%.
Image Source: Zacks Investment Research
SWTX Set to be Acquired by Merck KGaA
In April 2025, Merck KGaA, Darmstadt, Germany, announced that it had agreed to acquire SpringWorks for $47 per share in cash, representing a total equity value of approximately $3.9 billion.
The transaction is expected to be closed in the second half of 2025, subject to customary closing conditions.
The acquisition of SpringWorks will add its oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), to Merck KGaA’s portfolio.
Ogsiveo was approved in the United States for treating adult patients with desmoid tumors in November 2023. Ogsiveo is the first and only FDA-approved treatment indicated specifically for desmoid tumors.
Ogsiveo generated sales worth $172 million in 2024. In the first quarter of 2025, the drug recorded sales of $44.1 million in the United States.
Several label expansion studies on Ogsiveo, targeting different cancer indications, are currently ongoing.
Notably, the EMA validated the MAA for Ogsiveo for the treatment of adult patients with desmoid tumors in February 2024. The CHMP’s opinion related to the MAA for Ogsiveo is expected later in the second quarter of 2025.
The impending acquisition by Merck KGaA will help SpringWorks to reach global markets and build on the resources, helping more patients with such rare tumors.
SWTX's Zacks Rank & Stocks to Consider
SpringWorks currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Halozyme Therapeutics (HALO - Free Report) , Lexicon Pharmaceuticals (LXRX - Free Report) and Amarin (AMRN - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Halozyme’s earnings per share have increased from $5.02 to $5.23 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.56 to $6.77. Year to date, shares of HALO have risen 14.1%.
HALO’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.60%.
In the past 60 days, estimates for Lexicon’s loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 10.7%.
LXRX’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%.
In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 14.5%.
AMRN’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%.